Use of the SPARC microenvironment signature in the treatment of cancer

  • US 9,193,782 B2
  • Filed: 06/03/2011
  • Issued: 11/24/2015
  • Est. Priority Date: 06/03/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a human patient with a breast tumor exhibiting a SPARC microenvironment signature comprising:

  • (a) preparing a plurality of histological sections of the tumor to obtain a SPARC microenvironment signature by immunostaining a histological sections of the tumor with a first anti-SPARC antibody, wherein the first anti-SPARC antibody binds to the immunodominant epitopes bound by the anti-SPARC polyclonal antisera AF941, and immunostaining histological sections of the tumor with a second anti-SPARC antibody, wherein the second anti-SPARC antibody binds to the epitope bound by the anti-SPARC monoclonal antibody Mab941;

    (b) selecting a patient with a breast tumor having a SPARC microenvironment signature of least 70% of the tumor cells, fibroblasts, blood vessels, stroma and inflammatory cells staining positive with the first antibody, and at least 50% of the inflammatory cells and at least 70% of the blood vessels and stroma staining positive with the second antibody; and

    (c) administering a therapeutically effective amount of a chemotherapeutic regimen to the selected patient.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×